Cabaletta Bio, Inc. (CABA)
Largest Insider Buys in Sector
CABA Stock Price History Chart
CABA Stock Performance
About Cabaletta Bio, Inc.
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune …
Insider Activity of Cabaletta Bio, Inc.
Over the last 12 months, insiders at Cabaletta Bio, Inc. have bought $0 and sold $215,439 worth of Cabaletta Bio, Inc. stock.
On average, over the past 5 years, insiders at Cabaletta Bio, Inc. have bought $343,788 and sold $5.25M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 8,127 shares for transaction amount of $10,152 was made by Nichtberger Steven (President & CEO) on 2022‑10‑19.
List of Insider Buy and Sell Transactions, Cabaletta Bio, Inc.
| 2024-01-19 | Sale | See Remarks | 11,000 0.026% | $19.59 | $215,439 | -47.95% | ||
| 2023-12-19 | Sale | See Remarks | 11,000 0.0253% | $21.89 | $240,789 | -50.52% | ||
| 2023-11-20 | Sale | See Remarks | 11,000 0.0275% | $17.82 | $196,014 | -29.22% | ||
| 2023-10-19 | Sale | See Remarks | 11,000 0.0279% | $13.36 | $146,921 | +7.95% | ||
| 2023-09-19 | Sale | See Remarks | 11,000 0.028% | $17.57 | $193,220 | -10.54% | ||
| 2023-08-21 | Sale | See Remarks | 11,000 0.0273% | $13.42 | $147,583 | +16.03% | ||
| 2023-07-19 | Sale | See Remarks | 11,000 0.034% | $13.82 | $152,022 | +16.50% | ||
| 2023-06-20 | Sale | See Remarks | 11,000 0.0342% | $12.99 | $142,925 | +22.28% | ||
| 2023-05-19 | Sale | See Remarks | 22,000 0.0665% | $11.81 | $259,833 | +30.76% | ||
| 2022-10-19 | President & CEO | 8,127 0.0363% | $1.25 | $10,152 | +728.46% | |||
| 2022-10-18 | President & CEO | 141,873 0.6605% | $0.99 | $141,008 | +985.77% | |||
| 2022-10-18 | director | 125,000 0.572% | $0.98 | $122,121 | +985.77% | |||
| 2022-10-18 | Chief Financial Officer | 50,000 0.2324% | $0.99 | $49,620 | +985.77% | |||
| 2022-10-18 | See Remarks | 20,000 0.0932% | $0.99 | $19,894 | +985.77% | |||
| 2022-10-18 | director | 1,000 0.0047% | $0.99 | $994 | +985.77% | |||
| 2021-11-01 | Sale | 10 percent owner | 295,000 0.9416% | $13.00 | $3.83M | -88.24% | ||
| 2021-09-07 | Sale | 10 percent owner | 625,000 2.5876% | $9.70 | $6.06M | -80.47% | ||
| 2021-01-12 | Sale | 10 percent owner | 85,000 0.3201% | $13.00 | $1.1M | -24.23% | ||
| 2021-01-08 | Sale | 10 percent owner | 302,000 1.2423% | $13.00 | $3.93M | -16.84% | ||
| 2020-12-10 | Sale | 10 percent owner | 298,000 1.2174% | $14.75 | $4.4M | -27.72% |
Insider Historical Profitability
| Binder Gwendolyn | See Remarks | 20000 0.0409% | $2.34 | 1 | 9 | +985.77% |
| Nichtberger Steven | President & CEO | 986483 2.0183% | $2.34 | 2 | 0 | +857.12% |
| Flynn James E | 10 percent owner | 700000 1.4322% | $2.34 | 1 | 0 | +6.66% |
| 5AM Ventures V, L.P. | 10 percent owner | 333144 0.6816% | $2.34 | 1 | 5 | +6.66% |
| Simon Mark | director | 136144 0.2785% | $2.34 | 1 | 0 | +985.77% |
Institutional Investor Ownership
| BlackRock | $69.21M | 8.4 | 4.06M | -7.98% | -$6M | <0.01 | |
| State Street | $63.83M | 7.75 | 3.74M | +44.21% | +$19.57M | <0.01 | |
| JENNISON ASSOCIATES LLC | $58.4M | 7.09 | 3.42M | +110.43% | +$30.65M | 0.04 | |
| Alger | $53.06M | 6.44 | 3.11M | -6.52% | -$3.7M | 0.26 | |
| Adage Capital Partners Gp L L C | $51.81M | 6.29 | 3.04M | -7.04% | -$3.92M | 0.1 |